HeartBeam Appoints Alan Baumel as Chief Operating Officer
December 22 2021 - 8:31AM
Business Wire
Commercial Medical Device Veteran to Lead
Rollout of HeartBeam Platform Technology
HeartBeam, Inc. (NASDAQ: BEAT), a developmental stage
digital healthcare company with a proprietary ECG telemedicine
technology to bring new capabilities to cardiovascular disease, has
appointed Alan Baumel as Chief Operating Officer.
For over 35 years, Mr. Baumel has built a reputation as a highly
experienced product development, manufacturing, quality assurance,
and regulatory affairs professional. He has a strong record of
ensuring efficient and successful product commercial approvals and
launches at small and large organizations. Before joining
HeartBeam, Mr. Baumel was Program Director of the Case for Quality
Collaborative Community at Medical Device Innovation Consortium,
where he elevated the focus of all medical device stakeholders from
baseline quality and regulatory compliance to sustained, predictive
practices that advance medical device quality and safety to achieve
better patient outcomes. Previously he was Senior Vice President
overseeing Product Development, Manufacturing, Quality Assurance,
and Regulatory Affairs at Bardy Diagnostics (acquired by Hillrom),
a medical device venture that developed the first and only P-wave
centric ambulatory ECG monitor. He has also served with multiple
medical device companies, including W. L. Gore & Associates,
Ablation Frontiers (acquired by Medtronic), and Cameron Health
(acquired by Boston Scientific).
As Chief Operating Officer, which is a new role at HeartBeam,
Mr. Baumel will lead product development, manufacturing, quality
assurance, and regulatory affairs.
“On behalf of our board and management team, we are privileged
to be welcoming Alan to our Company, bringing over three decades of
leadership in the medical device industry working to deliver
products to market,” said Branislav Vajdic, PhD, Chief Executive
Officer and Founder of HeartBeam. “His extensive experience and
industry knowledge will be instrumental in accelerating our
commercialization path and FDA product development. Alan’s deep
experience, particularly with cardiac devices, is an ideal fit for
our heart attack detection and monitoring technology solutions.
Alan will not only solidify our core management team but also
prepare the Company to commercialize and scale our technology.”
Mr. Baumel added, “Being part of an innovative company that is
positioning itself to capture a large share of the MI detection
market is a perfect fit for me. My immediate goals will be to
enhance and streamline HeartBeam’s telehealth and ER software
product development and regulatory plan, improve overall operations
and move the Company toward its FDA studies and submissions and
subsequent product launches. I look forward to working with
Branislav and the team and leveraging my experience and clinical
relationships to drive HeartBeam’s commercialization success.”
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a development stage digital
healthcare company with proprietary ECG telemedicine technology
that will redefine the way high-risk cardiovascular patients are
diagnosed in an ambulatory setting at any time and any place. Its
breakthrough solution employs a reusable, credit card-sized, 3D
vector ECG recording device and cloud-based software capable of
assisting a physician in diagnosing a wide range of cardiovascular
diseases. HeartBeam is initially focusing on a huge unmet need of
helping diagnose heart attacks in patients outside of a medical
institution. No single lead ECG technology can offer patients and
their physicians this value. This underserved market is several
times larger than the cardiac arrhythmia detection market based on
the prevalence of patients with coronary artery disease at high
risk of heart attack. For more information, visit
www.heartbeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are “forward-looking statements.” While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our recently filed Registration Statement on Form S-1, which can
be found on the SEC’s website at www.sec.gov. We urge you to
consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue
reliance upon any such forward-looking statements, which speak only
as of the date made. Except as otherwise required by the federal
securities laws, we disclaim any obligation or undertaking to
publicly release any updates or revisions to any forward-looking
statement contained herein (or elsewhere) to reflect any change in
our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is
based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211222005084/en/
Media and Investor Relations Contact: Chris Tyson
Executive Vice President MZ North America Direct: 949-491-8235
BEAT@mzgroup.us www.mzgroup.us
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024